Farnesol promotes epithelial cell defense against Candida albicans through Toll-like receptor 2 expression, interleukin-6 and human β-defensin 2 production

被引:39
作者
Decanis, Nadege [1 ]
Savignac, Katia [1 ]
Rouabhia, Mahmoud [1 ]
机构
[1] Univ Laval, Fac Med Dent Pavillon Med Dent, Grp Rech Ecol Buccale, Quebec City, PQ G1V 0A6, Canada
基金
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词
Epithelial cells; Candida albicans; Farnesol; TLRs; Defensins; HUMAN ORAL-MUCOSA; ANTIMICROBIAL PEPTIDES; HUMAN KERATINOCYTES; ENDOTHELIAL-CELLS; IMMUNE-SYSTEM; DISEASE; SECRETION; INFECTION; PROTEINS; MOLECULE;
D O I
10.1016/j.cyto.2008.11.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Farnesol, a quorum-sensing molecule, regulates virulence and morphogenesis in Candida albicans and is involved in various human pathologies including oral candidiasis. Oral epithelial cells are involved in innate immunity against Candida infections via Toll-like receptors (TLRs) and inflammatory mediators. We investigated the effects of farnesol on host cells and its possible synergistic interaction with gingival epithelial cells against C. albicans infection by studying the expression of TLR2, 4 and 6. The production of IL-6, IL-8, and human beta-defensins 1 and 2 was also examined using engineered human oral mucosa tissue put in contact with various concentrations of farnesol with and without C. albicans. Our findings indicate that 24 h after contact with C. albicans, epithelial cells expressed more TLR2 than did non-infected cells. The addition of exogenous farnesol upregulated the TLR2 expression by the gingival epithelial cells in the presence or absence of C. albicans. In contrast, TLR4 was down regulated when farnesol was added to the tissue with or without C albicans. Finally, farnesol alone was shown to have no effect on TLR6, yet in the presence of both C. albicans and farnesol, TLR6 expression was down regulated. Farnesol modulated TLR2 expression by the epithelial cells following tissue contact with C albicans. This effect was paralleled by IL6 but not IL-8 secretion. Farnesol's effect on innate immunity was strengthened by its capacity to increase human beta-defensin 2 production, and by the efficacy of beta-defensin against C albicans growth. Overall results showed that exogenous farnesol promoted epithelial cell defense against C. albicans infection through the involvement of TLR2, IL-6, and human beta-defensin 2. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:132 / 140
页数:9
相关论文
共 50 条
  • [1] Toll-like receptor signalling
    Akira, S
    Takeda, K
    [J]. NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) : 499 - 511
  • [2] Porphyromonas gingivalis lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells
    Andrian, E
    Grenier, D
    Rouabhia, M
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 204 (01) : 178 - 183
  • [3] TLRs govern neutrophil activity in aspergillosis
    Bellocchio, S
    Moretti, S
    Perruccio, K
    Fallarino, F
    Bozza, S
    Montagnoli, C
    Mosci, P
    Lipford, GB
    Pitzurra, L
    Romani, L
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (12) : 7406 - 7415
  • [4] THE SKIN IMMUNE-SYSTEM - PROGRESS IN CUTANEOUS BIOLOGY
    BOS, JD
    KAPSENBERG, ML
    [J]. IMMUNOLOGY TODAY, 1993, 14 (02): : 75 - 78
  • [5] Toll-like receptors in the pathogenesis of human disease
    Cook, DN
    Pisetsky, DS
    Schwartz, DA
    [J]. NATURE IMMUNOLOGY, 2004, 5 (10) : 975 - 979
  • [6] Detection of β-defensins secreted by human oral epithelial cells
    Diamond, DL
    Kimball, JR
    Krisanaprakornkit, S
    Ganz, T
    Dale, BA
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 256 (1-2) : 65 - 76
  • [7] Textile design protection: Copyright, CAD and competition
    Dickson, K
    Coles, AM
    [J]. TECHNOVATION, 2000, 20 (01) : 47 - 53
  • [8] Candida albicans triggers interleukin-8 secretion by oral epithelial cells
    Dongari-Bagtzoglou, A
    Kashleva, H
    [J]. MICROBIAL PATHOGENESIS, 2003, 34 (04) : 169 - 177
  • [9] Ellepola AN, 2000, DENT UPDATE, V27, P114
  • [10] Oropharyngeal candidiasis: A review of its clinical spectrum and current therapies
    Epstein, JB
    Polsky, B
    [J]. CLINICAL THERAPEUTICS, 1998, 20 (01) : 40 - 57